Literature DB >> 10335449

Arylamine N-acetyltransferase activity in man.

I Cascorbi1, J Brockmöller, P M Mrozikiewicz, A Müller, I Roots.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10335449     DOI： 10.1081/dmr-100101932

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN： 0360-2532            Impact factor:   4.518


× No keyword cloud information.
  21 in total

1.  Influence of polymorphic metabolic enzymes on biotransformation and effects of diphenylmethane diisocyanate.

Authors:  Margareta Littorin; Saimei Hou; Karin Broberg; Jonas Björk; Susanne Fält; Galbani Abdoulaye; Malgorzata Kalemba; Charlotta Ryk; Staffan Skerfving
Journal:  Int Arch Occup Environ Health       Date:  2007-08-04       Impact factor: 3.015

2.  Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis.

Authors:  Musbah O M Tanira; Mehmet Simsek; Khalid Al Balushi; Khulood Al Lawatia; Hameedah Al Barawani; Riad A Bayoumi
Journal:  J Sci Res Med Sci       Date:  2003-08

3.  Heterocyclic amine intake, smoking, cytochrome P450 1A2 and N-acetylation phenotypes, and risk of colorectal adenoma in a multiethnic population.

Authors:  Jenna Voutsinas; Lynne R Wilkens; Adrian Franke; Thomas M Vogt; Lance A Yokochi; Robert Decker; Loïc Le Marchand
Journal:  Gut       Date:  2012-05-24       Impact factor: 23.059

Review 4.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

5.  N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease.

Authors:  Min Chen; Bing Xia; Bixiao Chen; Qiusha Guo; Jin Li; Mei Ye; Zhengguo Hu
Journal:  Can J Gastroenterol       Date:  2007-03       Impact factor: 3.522

6.  Meat-related mutagen exposure, xenobiotic metabolizing gene polymorphisms and the risk of advanced colorectal adenoma and cancer.

Authors:  Anne M J Gilsing; Sonja I Berndt; Elizabeth H Ruder; Barry I Graubard; Leah M Ferrucci; Laura Burdett; Joel L Weissfeld; Amanda J Cross; Rashmi Sinha
Journal:  Carcinogenesis       Date:  2012-05-02       Impact factor: 4.944

7.  Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.

Authors:  Elena A Gaikovitch; Ingolf Cascorbi; Przemyslaw M Mrozikiewicz; Jürgen Brockmöller; Roland Frötschl; Karla Köpke; Thomas Gerloff; Jury N Chernov; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2003-07-15       Impact factor: 2.953

Review 8.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

9.  Introducing pharmacy students to pharmacogenomic analysis.

Authors:  Evgeny Krynetskiy; Ina Lee Calligaro
Journal:  Am J Pharm Educ       Date:  2009-07-10       Impact factor: 2.047

10.  Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.

Authors:  R Salazar-González; R Gómez; S Romano-Moreno; S Medellín-Garibay; A Núñez-Ruíz; M Magaña-Aquino; R C Milán-Segovia; D P Portales-Pérez
Journal:  Mol Biol Rep       Date:  2014-08-28       Impact factor: 2.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.